Home › Funds › LMR Partners LLP › GSK
LMR Partners LLP position in GSK
GSK PLC · Health Care
LMR Partners LLP reported holding 980,479 shares of GSK (GSK PLC) in its Q2 2026 13F filing — a position valued at US$51.4M, representing 0.45% of its reported portfolio and ranking #35 among its reported holdings. LMR Partners LLP has disclosed GSK holdings in 10 of the last 10 reported quarters, going back to Q1 2024.
Last updated: 2026-10-24 · Source: SEC EDGAR Form 13F-HR
How LMR Partners LLP's GSK position evolved
LMR Partners LLP first disclosed a stake in GSK in Q1 2024 at 1,232,283 shares (US$52.8M). The position peaked in Q2 2024 at 3,331,458 shares, worth US$128.3M. Across 10 filings, LMR Partners LLP increased the stake 2 time(s), trimmed it 4 time(s) and left it unchanged 3 time(s). The most recent filing (Q2 2026) shows 980,479 shares valued at US$51.4M. Notable position changes include a 170% increase in Q2 2024 (shares rose 6% over the following quarter), a 91% trim in Q2 2025 (shares rose 12% over the following quarter), a 3918% increase in Q1 2026 (shares fell 5% over the following quarter).
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q1 2024 | 1.23M | $52.83M | New |
| Q2 2024 | 3.33M | $128.26M | Add |
| Q3 2024 | 2.02M | $82.54M | Reduce |
| Q4 2024 | 384.30K | $13.00M | Reduce |
| Q1 2025 | 384.30K | $14.89M | Hold |
| Q2 2025 | 32.70K | $1.26M | Reduce |
| Q3 2025 | 24.40K | $1.05M | Reduce |
| Q4 2025 | 24.40K | $1.20M | Hold |
| Q1 2026 | 980.48K | $54.11M | Add |
| Q2 2026 | 980.48K | $51.40M | Hold |
Dots on the line are colored by change type; missing quarters mean no position was reported.
About GSK and 13F data
GSK (GSK PLC) is a Health Care company. 23 other funds we track also report a position in GSK — the largest reported positions include Dodge & Cox (US$2.53B), DODGE & COX (US$2.53B), PRIMECAP MANAGEMENT CO/CA/ (US$1.32B). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding GSK
- Dodge & Cox 48.20M sh · $2.53B · Q2 2026
- DODGE & COX 48.20M sh · $2.53B · Q2 2026
- PRIMECAP MANAGEMENT CO/CA/ 25.18M sh · $1.32B · Q2 2026
- JTC Employer Solutions Trustee Ltd 8.59M sh · $450.31M · Q2 2026
- Mondrian Investment Partners LTD 4.97M sh · $239.21M · Q3 2026
- Grantham, Mayo, Van Otterloo & Co. LLC 3.60M sh · $188.69M · Q2 2026
- EQUITY INVESTMENT CORP 3.27M sh · $171.40M · Q2 2026
More on LMR Partners LLP
FAQ
How long has LMR Partners LLP held GSK?
LMR Partners LLP has disclosed GSK holdings in 10 of the last 10 reported quarters, going back to Q1 2024.
What is LMR Partners LLP's current position in GSK?
As of Q2 2026, LMR Partners LLP holds 980.48K shares of GSK (GSK PLC), valued at $51.40M, representing 0.45% of its reported portfolio and ranking #35.
Has LMR Partners LLP been buying or selling GSK?
In the latest 13F filing (Q2 2026), LMR Partners LLP held unchanged its position in GSK. The position peaked in Q2 2024 at 3.33M shares.
Which other funds hold GSK?
Other major institutional holders of GSK include Dodge & Cox, DODGE & COX, PRIMECAP MANAGEMENT CO/CA/, among 23 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.